Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Patients With Mature B-cell Malignancies

NCT06351527 is registered in ClinicalTrials.gov with InnoCare Pharma Inc. as lead sponsor.

NCT NCT06351527
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06351527 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Patients With Mature B-cell Malignancies
Lead sponsor
InnoCare Pharma Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
April 23, 2024
Completion date
October 25, 2027
Enrollment
78 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

mature b-cell malignancies